What is the purpose of this trial?
The purpose of the study is to evaluate whether rivaroxaban is superior to aspirin in reducing the risk of recurrent stroke and systemic embolism in patients with recent ESUS
Ages: 18 years and older
Bayer Healthcare Pharmaceuticals, Inc.
Dates: 08/29/2015 - 01/31/2018
Last Updated: 02/23/2016
Study HIC#: 1505015783